Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2008 Jun;10(6):587-93.
doi: 10.1016/j.ejheart.2008.04.008. Epub 2008 May 19.

The effect of Crataegus oxycantha Special Extract WS 1442 on clinical progression in patients with mild to moderate symptoms of heart failure

Suzanna M Zick  1 , Brenda Gillespie, Keith D Aaronson
Affiliations
Randomized Controlled Trial

The effect of Crataegus oxycantha Special Extract WS 1442 on clinical progression in patients with mild to moderate symptoms of heart failure

Suzanna M Zick et al. Eur J Heart Fail. 2008 Jun.

Abstract

Aim: To examine whether hawthorn (Crataegus Special Extract WS 1442 {CSE}) inhibits progression in heart failure (HF) patients.

Methods: We performed a retrospective analysis of data from the HERB CHF study in which patients with mild to moderate HF were randomised to either CSE 900 mg or placebo for 6 months. The primary outcome was time to progression of HF (HF death, hospitalisation, or sustained increase in diuretics) as assessed by log-rank tests and by Cox modelling.

Results: Progression of HF occurred in 46.6% of the CSE and 43.3% of the placebo groups (OR 1.14, 95% CI=0.56, 2.35: p=0.86). Patients receiving CSE were 3.9 times (95% CI=1.1-13.7: p=0.035) more likely to experience HF progression at baseline. In adjusted analysis, the risk of having early HF progression in the CSE group increased to 6.4 (95% CI=1.5, 26.5: p=0.011). In patients with LVEF< or =35%, those taking CSE were at significantly greater risk (3.2, 95% CI=1.3, 8.3: p=0.02) than the placebo group.

Conclusions: CSE does not reduce heart failure progression in patients who have HF. CSE appears to increase the early risk of HF progression.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest

Figures

Figure 1
Figure 1
Heart failure progression endpoints in the Crataegus Special Extract WS 1442 and placebo groups for the 120 patients in the HERB CHF trial.
Figure 2
Figure 2
Kaplan-Meier plot of the effect of Crataegus Special Extract WS 1442 versus placebo on progression of heart failure in patients in the HERB CHF trial. Crataegus Special Extract WS 1442 had no effect on the rate of heart failure progression (hazard ratio = 1.14, (95% CI = 0.56, 2.35)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hilfiker-Kleiner D, Landmesser U, Drexler H. Molecular Mechanisms in Heart Failure. Journal of the American College of Cardiology. 2006;48:A56–A66.
    1. Kuster GM, Kotlyar E, Rude MK, et al. Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation. 2005;111:420–427. - PubMed
    1. Weihmayr T, Ernst E. Therapeutic effectiveness of Crataegus. Fortschr Med. 1996;114:27–29. - PubMed
    1. Veveris M, Koch E, Chatterjee SS. Crataegus Special Extract WS 1442 improves cardiac function and reduces infarct size in a rat model of prolonged coronary ischemia and reperfusion. Life Sciences. 2004;74:1945–55. - PubMed
    1. Krzeminski T, Chatterjee SS. Ischemia and early reperfusion induced arrhythmias: beneficial effects of an extract of Crataegus oxyacantha L. Pharm Pharmacol Lett. 1993;3:45–8.

Publication types